Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Dexcom - What They Never Told You

The DexCom Stock Turnaround Is Showing Real Signs of Life

DexCom (DXCM) shares have put together an encouraging short-term bounce as the company maps out a multi-year growth algorithm. The stock currently carries a 8% “Sell” rating, but that’s up from the prior day’s 96% “Sell” rating and 100% “Sell” last week. A positive trend on that indicator. DXCM is...

DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day

DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and margin improvement. President and Chief Executive Officer Jake Leach said the company’s next phase

Are Wall Street Analysts Bullish on DexCom’s Stock?

Are Wall Street Analysts Bullish on DexCom’s Stock?

Although DexCom has significantly underperformed the broader market over the past year, Wall Street analysts continue to maintain a very bullish outlook on the company’s long-term growth prospects.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Sell in May and Go Away—Starting With These 3 Stocks

Oxford Club's Marc Lichtenfeld identifies three stocks worth selling in May—DexCom, Colgate-Palmolive, and Oracle—and breaks down the risks behind each call.

3 Reasons Analysts Love DexCom

Continuous glucose monitoring devices are vital to those with type 2 diabetes, and DexCom is cementing its position as a leader in this growing market.

DexCom’s Quarterly Earnings Preview: What You Need to Know

DexCom is set to report its first-quarter results at month-end, and the Street is expecting a solid double-digit expansion in earnings.

Is DexCom Stock Underperforming the Nasdaq?

DexCom has underperformed the Nasdaq Composite over the past year, yet analysts remain highly optimistic about the stock’s future.

inkl

Read news from The Economist, FT, and more,
with one subscription

What Are Wall Street Analysts' Target Price for DexCom Stock?

What Are Wall Street Analysts' Target Price for DexCom Stock?

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

5 things I hope to see on the Garmin Fenix 9, including the return of a smaller size

5 things I hope to see on the Garmin Fenix 9, including the return of a smaller size

The Garmin Fenix 9 could launch later this year and while it’s unlikely to be a major upgrade on the Fenix 8 Pro, I’m hoping to see these five features on a new watch.

Is DexCom Stock Underperforming the S&P 500?

Is DexCom Stock Underperforming the S&P 500?

DexCom has considerably underperformed the S&P 500 over the past year, but analysts are highly optimistic about the stock’s prospects.

DexCom Stock: Is Wall Street Bullish or Bearish?

DexCom Stock: Is Wall Street Bullish or Bearish?

Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.

Why TAL Education, Shake Shack And DexCom Just Appeared On Value Investors' Radars

Why TAL Education, Shake Shack And DexCom Just Appeared On Value Investors' Radars

A trio of stocks made an impressive leap in their Benzinga Edge value scores this week, with one standout making a 138% jump. The three companies that have caught the eye of value investors are TAL Education Inc (NYSE:TAL), Shake Shack Inc (NYSE:SHAK) and DexCom Inc (NASDAQ:DXCM).

From Dividends to Growth: Why These 3 Stocks Stand Out in 2025

From Dividends to Growth: Why These 3 Stocks Stand Out in 2025

Dividend stocks tend to be stable performers; these companies have a history of recent rallies or the potential to grow in the future.

DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor

DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor

DexCom Inc (NASDAQ:DXCM) is facing renewed scrutiny after three people with diabetes reportedly died following issues with its G7 continuous glucose monitor, according to adverse event filings submitted to the Food and Drug Administration in September.

Get all your
news in one place.

100's of premium titles.
One news app.

DexCom Earnings Preview: What to Expect

DexCom is scheduled to announce its fiscal third-quarter earnings later this month, and analysts project a double-digit profit rise.

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device.

Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside

These two companies could present an opportunity for investors to gain access while they are relatively undervalued and before they appreciate once again.

How Is DexCom's Performance Compared to Other Medical Device Companies?

DexCom has outperformed the broader medical devices industry over the past year, and analysts remain strongly bullish on the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

DexCom, GE, SLB: Why Experts Rate These Stocks at Strong Buy

Wall Street gives these three diverse names Strong Buy recommendations with high potential upside.

DexCom Stock: Analyst Estimates & Ratings

Despite DexCom’s underwhelming price action, Wall Street analysts appear highly optimistic about its prospects.

What You Need to Know Ahead of DexCom’s Earnings Release

DexCom is all geared up to announce its second-quarter earnings towards the end of this month, and analysts anticipate a single-digit bottom-line growth.

2 ‘Strong Buy’ Stocks That the MAHA Movement AND Wall Street Love

Policies associated with the MAHA movement could boost these two stocks significantly.

International Business Times UK

Diabetics at Risk: FDA Issues Highest-Level Recall on 2M Dexcom Devices Over 'Deadly Fault'

The FDA has recalled 2 million Dexcom glucose monitors due to a serious safety risk. Learn how diabetic patients should act immediately to protect their health.

DexCom Stock: Is DXCM Underperforming the Health Care Sector?

DexCom has underperformed the Health Care sector over the past year, but analysts are highly optimistic about the stock’s prospects.

Android Central

Garmin has patented long-term blood glucose tracking; here's how it'd work

Garmin watches already pair with Dexcom for indirect blood glucose monitoring. This patent shows how Garmin watches could directly help diabetics.

1 2 3 4

People

Robert F. Kennedy Jr

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the Food and Drug Administration

Abbott Laboratories

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

380,494 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play